Nephrocare Health Services Ltd
Incorporated in 2010, Nephrocare Health Services Ltd. provides end-to-end dialysis care through a wide network of clinics across India and select international markets.[1]
- Market Cap ₹ 6,526 Cr.
- Current Price ₹ 649
- High / Low ₹ 782 / 445
- Stock P/E
- Book Value ₹ 96.8
- Dividend Yield 0.00 %
- ROCE 5.65 %
- ROE -1.38 %
- Face Value ₹ 2.00
Pros
- Company has reduced debt.
- Company is almost debt free.
Cons
- Stock is trading at 6.71 times its book value
- Company has low interest coverage ratio.
- Company has a low return on equity of 1.71% over last 3 years.
- Company's cost of borrowing seems high
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|
| 284 | 317 | 386 | 436 | 544 | 630 | 651 | |
| 247 | 299 | 348 | 384 | 449 | 541 | 559 | |
| Operating Profit | 38 | 18 | 38 | 52 | 95 | 89 | 93 |
| OPM % | 13% | 6% | 10% | 12% | 17% | 14% | 14% |
| 5 | 4 | 5 | 8 | 16 | 15 | 19 | |
| Interest | 7 | 10 | 15 | 17 | 14 | 50 | 47 |
| Depreciation | 34 | 39 | 41 | 43 | 51 | 58 | 58 |
| Profit before tax | 1 | -28 | -13 | 0 | 45 | -4 | 6 |
| Tax % | 22% | -22% | 20% | -1,668% | 25% | 114% | |
| 1 | -22 | -15 | 4 | 34 | -8 | -1 | |
| EPS in Rs | 5.57 | -110.19 | -77.01 | 18.76 | 164.24 | -0.80 | -14.74 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 17% |
| 3 Years: | 18% |
| TTM: | 16% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 10% |
| TTM: | -130% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | % |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 0% |
| 3 Years: | 2% |
| Last Year: | -1% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|
| Equity Capital | 2 | 2 | 2 | 2 | 2 | 20 |
| Reserves | 246 | 407 | 392 | 399 | 540 | 951 |
| 140 | 119 | 200 | 182 | 133 | 12 | |
| 32 | 45 | 54 | 82 | 81 | 152 | |
| Total Liabilities | 419 | 572 | 647 | 665 | 757 | 1,135 |
| 159 | 167 | 169 | 219 | 234 | 245 | |
| CWIP | 0 | 2 | 3 | 1 | 4 | 4 |
| Investments | 47 | 110 | 148 | 149 | 212 | 335 |
| 212 | 293 | 328 | 297 | 306 | 551 | |
| Total Assets | 419 | 572 | 647 | 665 | 757 | 1,135 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|
| 33 | 12 | 11 | 57 | 80 | 133 | |
| -64 | -167 | -75 | -23 | -104 | -299 | |
| 36 | 147 | 63 | -36 | 26 | 256 | |
| Net Cash Flow | 4 | -8 | -0 | -1 | 2 | 90 |
| Free Cash Flow | -18 | -31 | -28 | -18 | -1 | 57 |
| CFO/OP | 51% | 93% | 19% | 120% | 80% | 169% |
Ratios
Standalone / View Consolidated
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|
| Debtor Days | 98 | 106 | 122 | 116 | 130 | 126 |
| Inventory Days | 65 | 50 | 61 | 51 | ||
| Days Payable | 56 | 52 | 40 | 108 | ||
| Cash Conversion Cycle | 107 | 104 | 143 | 59 | 130 | 126 |
| Working Capital Days | 21 | 48 | 116 | 58 | 62 | 56 |
| ROCE % | -4% | 0% | 3% | 9% | 6% |
Insights
In beta| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|
| Machine Utilization Rate % |
|
|||||
| International Revenue Share % |
||||||
| Number of Active Guests (Patients) guests |
||||||
| Number of Dialysis Machines machines |
||||||
| Number of Dialysis Treatments (Sessions) sessions |
||||||
| Number of PPP (Public-Private Partnership) Clinics clinics |
||||||
| Revenue per Treatment (RPT) INR |
||||||
| Total Number of Dialysis Clinics clinics |
||||||
Extracted by Screener AI
Documents
Announcements
- Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
-
Closure of Trading Window
- Trading window closes from October 1, 2026 until 48 hours after Q2/H1 FY26 results.
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
- Company to attend PL Capital investor conference on September 29, 2026 in Mumbai.
-
Announcement under Regulation 30 (LODR)-Credit Rating
- India Ratings upgrades bank loan facilities to IND AA-/Stable and affirms short-term IND A1+ on Sept. 18, 2026.
-
Announcement under Regulation 30 (LODR)-Restructuring
- Board approved consolidation of Philippines step-down subsidiaries on September 18, 2026.
Annual reports
-
Annual Report 2026
from bse
-
Annual Report 2025
from web
-
Annual Report 2024
from web
-
Annual Report 2023
from web
Concalls
-
Aug 2026Transcript PPT REC
-
May 2026Transcript PPT REC
-
Feb 2026Transcript PPT REC
Business Profile[1]
Nephrocare Health Services Limited (NHSL) is India’s largest dialysis-care provider offering a full spectrum of renal-care services haemodialysis, peritoneal dialysis, home haemodialysis, dialysis-on-call, dialysis-on-wheels, pharmacy support, diagnostics, and wellness management. It operates through captive hospital-based clinics, standalone centres, and large Public-Private Partnership (PPP) units.